Multicenter research survey of radical radiotherapy for endometiral cancer and Analysis of appropriate dosimetry The Gynecological Oncology group of Japanese Radiation Oncology Study Group

Multicenter research survey of radical radiotherapy for endometiral cancer and Analysis of appropriate dosimetry The Gynecological Oncology group of Japanese Radiation Oncology Study Group - Multicenter research survey of radical radiotherapy for endometiral cancer and Analysis of appropriate dosimetry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052644

Enrollment

120

Registered

2023-11-01

Start date

2023-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (a) Histopathologically confirmed to be endometrial cancer (adenocarcinoma, adenosquamous carcinoma), FIGO stage I-IVA. (b) The patient has undergone radical treatment for uterine cancer between 1 January 2008 and 31 December 2017 at this hospital and at the respective performing institution. (b) Patients who underwent radical radiotherapy (external-beam radiation combined with Brachytherapy or Brachytherapy alone) for endometrial cancer at this hospital or at the respective centre between 1 January 2008 and 31 December 2017 and were followed up for at least 2 years. However, cases who died within 2 years are included, as they may have died of cancer or accidental death within 2 years. (c) Age is 20 years or older at the start of treatment. (d) Cases were treated for the first time for endometrial cancer.

Exclusion criteria

Exclusion criteria: (a) patients who refused to register their data (b) Patients who had external radiotherapy with particle radiotherapy. (c) Patients with a history of pelvic irradiation. (d) Patients with active overlapping cancers. (e) Patients who have not received a curative dose as radiotherapy for endometrial cancer. Specifically, patients with pelvic doses of less than 30 Gy when combined with external irradiation and patients who have not undergone Brachytherapy should be excluded. (f) Other cases deemed inappropriate by the physician in charge.

Design outcomes

Primary

Measure	Time frame
Overall survival rate	—

Secondary

Measure	Time frame
Local control rate, pelvic control rate, recurrence-free survival rate, distant regression-free survival rate, rectal late adverse events, bladder late adverse events,Dosimetry.	—

Countries

Japan

Contacts

Public ContactYuko Kaneyasu

National Hospital Organisation Fukuyama Medical Centre Department of Radiation Oncology

kaneyasuyuko@gmail.com084-922-0001

Outcome results